Integra LifeSciences Holdings Aktie
WKN DE: 897013 / ISIN: US4579852082
31.07.2025 13:07:32
|
Integra LifeSciences Q2 Results Beat Expectations
(RTTNews) - Integra LifeSciences Holdings Corporation (IART), a medical technology company, Thursday reported net loss of $484.07 million or $6.31 per share for the second quarter, significantly higher than $12.40 million or $0.16 per share loss in the same quarter a year ago, primary due to a goodwill impairment charge of $511.37 million.
Excluding one-time items, the company posted adjusted earnings of $34.37 million or $0.45 per share, down from $49.01 million or $0.63 per share in the prior year.
On average, 10 analysts expected earnings of $0.43 per share. Analysts' estimates typically exclude special items.
Operating loss widened to $512.67 million from $3.03 million loss last year.
Adjusted EBITDA, or adjusted earnings before interest, taxes, depreciation, and amortization decreased to $71.22 million from $83.76 million a year ago.
Revenue for the quarter slightly declined to $415.61 million from $418.18 million in the previous year. The consensus estimate was for $395.06 million.
For the third quarter, the company expects revenues to be in the range of $410 million to $420 million, a growth of 7.7% - 10.3%. Adjusted EPS is expected between $0.40 and $0.45. Analysts expect the company to report earnings of $0.58 per share on revenue of $418.83 million.
For the full year, Integra LifeSciences is updating its revenue guidance to $1.655 billion - $1.680 billion form the previous $1.650 billion - $1.715 billion. It has confirmed its adjusted EPS outlook of $2.19 - $2.29. The Street is looking for earnings of $2.24 per share with revenue of $1.67 billion.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Integra LifeSciences Holdings Corp.mehr Nachrichten
06.10.25 |
NASDAQ Composite Index-Papier Integra LifeSciences-Aktie: So viel Verlust hätte ein Integra LifeSciences-Investment von vor 10 Jahren eingefahren (finanzen.at) | |
03.10.25 |
Schwache Performance in New York: NASDAQ Composite im Minus (finanzen.at) | |
02.10.25 |
Gute Stimmung in New York: NASDAQ Composite schlussendlich in Grün (finanzen.at) | |
02.10.25 |
NASDAQ-Handel: NASDAQ Composite legt nachmittags zu (finanzen.at) | |
02.10.25 |
Gute Stimmung in New York: NASDAQ Composite bewegt sich am Mittag im Plus (finanzen.at) | |
30.09.25 |
NASDAQ Composite-Handel aktuell: NASDAQ Composite schlussendlich mit positivem Vorzeichen (finanzen.at) | |
29.09.25 |
NASDAQ Composite Index-Titel Integra LifeSciences-Aktie: So viel Verlust hätte eine Investition in Integra LifeSciences von vor 5 Jahren bedeutet (finanzen.at) | |
25.09.25 |
Anleger in New York halten sich zurück: NASDAQ Composite sackt ab (finanzen.at) |
Analysen zu Integra LifeSciences Holdings Corp.mehr Analysen
Aktien in diesem Artikel
Integra LifeSciences Holdings Corp. | 12,30 | 0,82% |
|